An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients.
Knopman, D
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. [electronic resource] - Alzheimer disease and associated disorders - 162-5 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
0893-0341
10.1097/00002093-200107000-00008 doi
Administration, Oral
Aged
Aged, 80 and over
Alzheimer Disease--drug therapy
Betaine--adverse effects
Cognition Disorders--drug therapy
Disease Progression
Female
Gastrointestinal Agents--adverse effects
Homocysteine--metabolism
Humans
Male
Mental Status Schedule
Middle Aged
Risk Factors
Treatment Outcome
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. [electronic resource] - Alzheimer disease and associated disorders - 162-5 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
0893-0341
10.1097/00002093-200107000-00008 doi
Administration, Oral
Aged
Aged, 80 and over
Alzheimer Disease--drug therapy
Betaine--adverse effects
Cognition Disorders--drug therapy
Disease Progression
Female
Gastrointestinal Agents--adverse effects
Homocysteine--metabolism
Humans
Male
Mental Status Schedule
Middle Aged
Risk Factors
Treatment Outcome